In Vitro Activity of the Novel Pleuromutilin Lefamulin (BC-3781) and Effect of Efflux Pump Inactivation on Multidrug-Resistant and Extensively Drug-Resistant Neisseria gonorrhoeae-Reference-Cited by-同舟云学术

In Vitro Activity of the Novel Pleuromutilin Lefamulin (BC-3781) and Effect of Efflux Pump Inactivation on Multidrug-Resistant and Extensively Drug-Resistant Neisseria gonorrhoeae

Published:2017-11 Issue:11 Volume:61 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Jacobsson Susanne¹,Paukner Susanne²,Golparian Daniel¹,Jensen Jörgen S.³^ORCID,Unemo Magnus¹

Affiliation:

1. WHO Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections, National Reference Laboratory for Pathogenic Neisseria, Department of Laboratory Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden

2. Nabriva Therapeutics AG, Vienna, Austria

3. Department of Microbiology and Infection Control, Sexually Transmitted Infections, Research and Development, Statens Serum Institut, Copenhagen, Denmark

Abstract

ABSTRACT We evaluated the activity of the novel semisynthetic pleuromutilin lefamulin, inhibiting protein synthesis and growth, and the effect of efflux pump inactivation on clinical gonococcal isolates and reference strains ( n = 251), including numerous multidrug-resistant and extensively drug-resistant isolates. Lefamulin showed potent activity against all gonococcal isolates, and no significant cross-resistance to other antimicrobials was identified. Further studies of lefamulin are warranted, including in vitro selection and mechanisms of resistance, pharmacokinetics/pharmacodynamics, optimal dosing, and performance in randomized controlled trials.

Funder

Örebro County Council Research Committee

Foundation for Medical Research at Örebro University Hospital

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01497-17

Reference22 articles.

1. Antimicrobial Resistance in Neisseria gonorrhoeae in the 21st Century: Past, Evolution, and Future

2. WHO. 2016. WHO guidelines for the treatment of Neisseria gonorrhoeae. World Health Organization, Geneva, Switzerland.

3. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults

4. Sexually transmitted diseases treatment guidelines, 2015;Workowski KA;MMWR Recomm Rep,2015

5. Public Health Agency of Canada. 2013. Gonococcal infections. In Canadian guidelines on sexually transmitted infections. https://www.canada.ca/en/public-health/services/infectious-diseases/sexual-health-sexually-transmitted-infections/canadian-guidelines/sexually-transmitted-infections/canadian-guidelines-sexually-transmitted-infections-34.html.

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel pleuromutilin derivatives conjugated with phenyl-sulfide and boron-containing moieties as potent antibacterial agents against antibiotic-resistant bacteria;European Journal of Medicinal Chemistry;2024-11

2. Immunoinformatics strategy for designing a multi-epitope chimeric vaccine to combat Neisseria gonorrhoeae;Vacunas;2024-07

3. Immunoinformatics strategy for designing a multi-epitope chimeric vaccine to combat Neisseria gonorrhoeae;Vacunas (English Edition);2024-07

4. The novel 2024 WHO Neisseria gonorrhoeae reference strains for global quality assurance of laboratory investigations and superseded WHO N. gonorrhoeae reference strains—phenotypic, genetic and reference genome characterization;Journal of Antimicrobial Chemotherapy;2024-06-21

5. Antimicrobial treatment and resistance in sexually transmitted bacterial infections;Nature Reviews Microbiology;2024-03-20